Drugs / INDV-2000
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05694533 | Mar → Apr 2023 | — | Indivior Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04976855 | Aug 2022 → Jul 2023 | opiate dependence | Indivior Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04413552 | Jul 2020 → Apr 2021 | opiate dependence | Indivior Inc. | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT06384157 | Jun 2024 → Sep 2025 | substance-related disorder | Indivior Inc. | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-04-30 | Indivior Inc. | Results Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance indivior.com ↗
INDV-2000 did not meet the primary endpoint of "no treatment failure." |
All press releases naming this drug 2 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INDV-2000 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06384157 ↗ |
| Known as | C4X_3256 | “INDV-2000 (C4X_3256) Under Fasting and Fed Conditions” NCT04413552 ↗1“INDV-2000 (C4X_3256) up to 28 Days” NCT04976855 ↗ |
| Action | Inhibit | “OX1R antagonist” NCT06384157 ↗ |
| Route | Oral | “Participants will receive a single dose of INDV-2000 orally on Day 1 under fasted conditions” NCT04413552 ↗ |